Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase
Source: Streetwise Reports
June 27, 2018 (Investorideas.com Newswire) This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery.
In a June 26 press release, ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced it has advanced antibody candidates against a pair of targets suspected to cause neurodegenerative disease to the second phase of its discovery platform. The targets are "aggregated, toxic oligomers of alpha-synuclein, implicated in the development of Parkinson's disease (PD), as well as TDP43 (TAR DNA binding protein), implicated in the development of ALS [amyotrophic lateral sclerosis],"according to the release.
The company's lead candidate, PMN310, targets Alzheimer's disease, also a prominent neurodegenerative indication.
In the announcement, ProMIS' chief science officer, Dr. Neil Cashman, explained the company's two-phase discovery platform.
"The first stage involves predicting novel epitope targets and using these to generate large numbers of candidate antibodies. The second stage is to validate selectivity, functional activity, and select the best leads," Cashman stated.
The press release notes "hundreds of monoclonal antibodies have been generated against these predicted disease-specific epitopes and ProMIS has now begun the validation and prioritization process to select therapeutic candidates displaying an ideal, highly selective product profile against these targets."
Noting progression into the second phase of discovery complies with the company's corporate strategy, ProMIS executive chairman Gene Williams stated, "We are actively pursuing discussions with large pharma regarding partnering of these two new toxic oligomer programs."
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.